Bioinformatic Identification of SCP2 as a Novel Prognostic and Immunological Biomarker for Colorectal Cancer
This study identifies SCP2 as a novel independent prognostic and immunological biomarker for colorectal cancer, demonstrating that its downregulation correlates with poor clinical outcomes, advanced disease stages, an immunosuppressive microenvironment, and enhanced tumor cell proliferation.